Longevity & Aging · Diets · Metabolic & Cardiometabolic

Mediterranean diet decreases cardiovascular disease

In plain terms: Does a Mediterranean diet lower heart attack and stroke risk?

Strong support Longevity & Aging

Part of: 🥗 mediterranean diet

RefutedContestedStrong support

consensus score 0.83

Yes — among the strongest diet evidence, mostly from fewer strokes.

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

13 support 0 contradict 0 tested null 3 mixed · 16 sources, 13 independent groups · 3 superseded — pooled inside a review, counted once

What the evidence shows

The Mediterranean diet (+olive oil/+nuts) reduced major cardiovascular events ~30% in high-risk adults - the strongest CAUSAL longevity-diet evidence, but a flawed pillar: the original trial was retracted for a randomization breach and republished (effect survived), industry-funded, benefit driven mainly by stroke.

Cochrane agrees with us see how our grade compares ▾

Cochrane · low-to-moderate: moderate-quality evidence for reduction in strokes Agrees with our grade

primary prevention, PREDIMED); low-quality evidence for reduction in total and CVD mortality; paucity of evidence for secondary prevention

“Despite the relatively large number of studies included in this review, there is still some uncertainty regarding the effects of a Mediterranean-style diet on clinical endpoints and CVD risk factors for both primary and secondary prevention. The quality of evidence for the modest benefits on CVD risk factors in primary prevention is low or moderate, with a small number of studies reporting minimal harms. There is a paucity of evidence for secondary prevention.”

Why we agree: we reached the same direction independently, from our own appraisal of 16 sources. Two methods landing in the same place is a stronger signal than either alone.

What is Cochrane, and why trust it?

Cochrane produces systematic reviews: instead of running a new study, they gather every trial ever done on a question, judge how well each was run, and pool the results. They take no commercial or industry funding, which is why the medical community treats their reviews as a gold standard — and why we check our own verdicts against theirs.

About Cochrane ↗ · Get involved / support ↗

Read the Cochrane review ↗

The evidence (19)

Source	Grade	Stance	Quality	Finding
Martínez-González MA et al 2026 · study_type: RCT	RCT	mixed	moderate	PREDIMED: CVD HR 0.84 (0.61-1.15, ns) excl. wine, 0.55 (0.36-0.83) incl. wine; SUN cohort CVD assoc. ns
Karam 2023 · BMJ	meta-analysis	supports	high	[FT-verified] FT BMJ network-MA all-cause mortality OR0.72 (0.56-0.92) MODERATE GRADE
Sofi 2008 · BMJ	observational	supports	moderate	Meta-analysis: 2-point higher Mediterranean adherence associated with 9% lower CV mortality and 9% lower overall mortality.
Sebastian 2024 · Curr Probl Cardiol	meta-analysis	supports	moderate	MA of RCTs (PREDIMED, CORDIOPREV, Lyon): MedDiet reduces cardiovascular events vs control
Delgado-Lista J et al. 2026 · Eur J Intern Med	RCT	supports	high	CORDIOPREV RCT (n=1002, 7-yr secondary prevention): higher adherence lowered MACE (HR ~0.14 highest vs lowest) - but a low-fat diet performed comparably, so the benefit tracks adherence/diet quality, not Mediterranean-specificity.
Arenas-Montes J et al 2026 · study_type: RCT	RCT	mixed	moderate	CORDIOPREV secondary analysis: MACE recurrence HR 1.42 (1.01-2.00) with high postprandial LPS; MED diet lower MACE risk than LF diet only in LPS subgroup
Estruch R, et al. (PREDIMED, republished) 2018 · N Engl J Med	RCT	supports	high	PROVENANCE FLAG: 2013 PREDIMED retracted for randomization errors, republished 2018 corrected; effect persisted ↩ SUPERSEDED — pooled in the review above, counted once
Doundoulakis 2024 · Nutr Rev	meta-analysis	supports	moderate	Network MA of dietary RCTs with hard CV outcomes: MedDiet among most effective for reducing CV events
Delgado-Lista 2022 · Lancet	RCT	supports	high	CORDIOPREV 7-yr RCT (n=1002 CHD patients): Mediterranean diet superior to low-fat for secondary prevention of major CV events. ↩ SUPERSEDED — pooled in the review above, counted once
Guasch-Ferre 2014 · BMC Med	observational	supports	moderate	PREDIMED cohort analysis: higher olive oil (esp. extra-virgin) intake associated with lower CVD events and cardiovascular mortality.
Rosato 2019 · Eur J Nutr	meta-analysis	supports	high	SR/meta of cohorts + RCTs: high Mediterranean adherence associated with ~15-30% lower CVD incidence and CHD/stroke.
Volpe R et al. 2025 · Nutrition	meta-analysis	supports	high	Meta 19 studies (>91,000): higher Mediterranean-diet adherence lowered major CV events (RCT RR 0.44; cohort RR 0.95) and mortality; effects on BP and lipids were not significant.
Becerra-Tomás N et al 2020 · study_type: meta-analysis	meta-analysis	supports	moderate	RCT pooled: CVD incidence RR 0.62 (0.50-0.78), MI RR 0.65 (0.49-0.88); cohorts: CVD-mortality RR 0.79, stroke RR 0.80
Ungvari 2025 2025 · GeroScience	meta-analysis	supports	moderate	[FT-verified] GeroScience MA 30 studies vs stroke; pooled HR favorable
Fung 2009 · Circulation	observational	supports	high	Nurses' Health Study (n~74886 women): top Mediterranean-adherence quintile had lower incident CHD, stroke and CVD mortality. ↩ SUPERSEDED — pooled in the review above, counted once
Ahmadirad H et al 2026 · study_type: meta-analysis	meta-analysis	mixed	moderate	MIND diet MA (23 cohorts): CVD-mortality RR 0.78 (0.67-0.90) significant; CVD incidence RR 0.86 (0.68-1.08) NOT significant
Li Y et al 2026 · study_type: observational	observational	supports	moderate	Target-trial emulation, NHS/HPFS: 20-y CVD (MI/revasc/stroke/CV-death) risk ratio 0.79 (0.70-0.91) high-risk; 0.90 (0.84-0.95) general pop
de Lorgeril 1999 · Circulation	RCT	supports	high	Lyon Diet Heart secondary-prevention RCT: Mediterranean-style diet cut cardiac death + nonfatal MI ~50-70% post-MI.
Golzarand M et al 2026 · study_type: observational	observational	supports	moderate	Tehran Lipid & Glucose cohort, 10.6y: high MedDiet score + low UPF intake CHD HR 0.47 (0.29-0.75); high MedDiet even w/ high UPF HR 0.50 (0.31-0.83)

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.